Efficacy of anti-IgE therapy in patients with atopic dermatitis
Authors:
- Paul G. VigoPVPaul G. Vigo
- Khaled R. GirgisKGKhaled R. Girgis
- Bruce L. PfuetzeBPBruce L. Pfuetze
- Michael E. CritchlowMCMichael E. Critchlow
- Joe FisherJFJoe Fisher
- Iftikhar HussainIHIftikhar Hussain
- 1 July 2006
- journal article
- research article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 55 (1) , 168-170
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Failure of omalizumab for treatment of severe adult atopic dermatitisJournal of the American Academy of Dermatology, 2005
- Efficacy and Safety of Pimecrolimus Cream in the Long-Term Management of Atopic Dermatitis in ChildrenPediatrics, 2002
- Effect of Omalizumab on Symptoms of Seasonal Allergic RhinitisA Randomized Controlled TrialJAMA, 2001
- Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthmaJournal of Allergy and Clinical Immunology, 2001
- Treatment of Allergic Asthma with Monoclonal Anti-IgE AntibodyNew England Journal of Medicine, 1999
- Peak flow variability, methacholine responsiveness and atopy as markers for detecting different wheezing phenotypes in childhoodThorax, 1997
- Serum IgE concentration in atopic dermatitisJournal of Allergy and Clinical Immunology, 1974